EP1292295A1 - Supplement visant augmenter la fertilite - Google Patents

Supplement visant augmenter la fertilite

Info

Publication number
EP1292295A1
EP1292295A1 EP01940729A EP01940729A EP1292295A1 EP 1292295 A1 EP1292295 A1 EP 1292295A1 EP 01940729 A EP01940729 A EP 01940729A EP 01940729 A EP01940729 A EP 01940729A EP 1292295 A1 EP1292295 A1 EP 1292295A1
Authority
EP
European Patent Office
Prior art keywords
supplement
dha
admixture
spermatozoa
antioxidant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01940729A
Other languages
German (de)
English (en)
Inventor
Ray Clifford Noble
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JSR Clover Ltd
Original Assignee
JSR Clover Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JSR Clover Ltd filed Critical JSR Clover Ltd
Publication of EP1292295A1 publication Critical patent/EP1292295A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Definitions

  • This invention is concerned with the provision of a supplement by oral or other means and in particular one that exhibits properties for promoting and enhancing fertility and reproductive output in mammals such as livestock and particularly pigs.
  • spermatozoa and associated seminal plasma contain lipids (fat) which have been found to be unique in their composition and fatty acid constituents when compared with almost all other tissues within the male animal body.
  • lipids fat
  • fatty acid constituents when compared with almost all other tissues within the male animal body.
  • all tissues have a requirement to maintain significant levels of essential polyunsaturated fatty acids.
  • These usually exist as C18 components, linoleic and alpha-linolenic acids, which are distributed between phospholipid and neutral lipid fractions.
  • Such acids are also accompanied by varying, but usually very much lower, concentrations of longer chain acids of higher polyunsaturation.
  • long chain acids can either be derived directly through nutrition or indirectly through synthesis by processes within the tissues themselves involving interrelated desaturation (introduction of more double bonds) and chain elongation (addition of more carbon atoms) of both linoleic and alpha-linolenic acid.
  • a selection of C20 and C22 polyunsaturates can arise from linoleic acid and these are known collectively as n-6 or omega-6 polyunsaturates.
  • n-6 or omega-6 polyunsaturates a series of C20 and C22 polyunsaturates arise from alpha-linolenic acid and are collectively known as n-3 or omega-3 polyunsaturates.
  • the male pig has a substantial level of polyunsaturates present within its spermatozoa and seminal fluid which is characteristically dominated by docosahexaenoic acid (DHA) of which its chain length is 22 carbon atoms with 6 double bonds in n-3 configuration and docosapentaenoic acid (DPA) of which its chain length is 22 carbon atoms with 5 double bonds in n-6 configuration.
  • DHA docosahexaenoic acid
  • DPA docosapentaenoic acid
  • the present invention was developed to address the issues of maximising financial gain from commercial pig breeding by way of optimising male fertility whilst additionally increasing female reproductive output.
  • the object of the present invention was to produce a supplement for easy use and which was adapted to maximise the fertility and reproductive output in pigs.
  • a supplement for the promotion of fertility and reproductive output in animals comprising an admixture of an enriched triacylglycerol source of Docosahexaenoic acid (DHA) accompanied by at least one antioxidant and selenium as the major cationic enzyme co-factor to protect the DHA.
  • DHA Docosahexaenoic acid
  • a supplement for the promotion of fertility and reproductive output in humans comprising an admixture of an enriched triacylglycerol source of Docosahexaenoic acid (DHA) accompanied by at least one antioxidant and selenium as the major cationic enzyme co-factor to protect the DHA.
  • DHA Docosahexaenoic acid
  • GLA gamma-linolenic acid
  • a supplement for the promotion of fertility and reproductive output in animals comprising an admixture of an enriched triacylglycerol source of Docosahexaenoic acid (DHA) accompanied by at least one antioxidant, selenium as the major cationic enzyme co-factor to protect the DHA and gamma-linolenic acid (GLA).
  • DHA Docosahexaenoic acid
  • GLA gamma-linolenic acid
  • a supplement for the promotion of fertility and reproductive output in humans comprising an admixture of an enriched triacylglycerol source of Docosahexaenoic acid (DHA) accompanied by at least one antioxidant, selenium as the major cationic enzyme co-factor to protect the DHA and gamma-linolenic acid (GLA).
  • DHA Docosahexaenoic acid
  • GLA gamma-linolenic acid
  • the DHA is present in the admixture at a level of 63-90g/kg.
  • the GLA is present in the admixture at a level of 4-10g/kg and advantageously is introduced in the form of oil from the Evening Primrose or Starflower.
  • the antioxidant is alpha-tocopherol and present in the admixture at a minimum of lOOOmg/kg.
  • the selenium is present in the admixture at a minimum 2.75mg/kg.
  • stearadonic acid an n-3 C18 polyunsaturated acid
  • n-3 C18 polyunsaturated acid may be added to the admixture.
  • the admixture can be introduced into the animal by way of a suitable carrier for ingestion by the animal such as feedstuff s or by gelatin bolus.
  • a suitable carrier for ingestion by the animal such as feedstuff s or by gelatin bolus.
  • the fatty acids, antioxidants and cationic cofactors can be supplied intramuscularly, intraperitonealy, intravenously or subcutaneously for slow release and appropriate tissue targeting as chelates, chemical complexes and adjuncts.
  • the properties of the supplement promote increased fertility in both the male and female animals.
  • the properties of the supplement increased significantly a wide range of qualitative and quantitative biochemical/ physiological parameters of the semen and its spermatozoa resulting in the promotion of the t fertilising capacity of the ejaculate.
  • the application to gilts/ sows of such semen from boars supplemented with the admixture resulted in a significant elevation to female reproductive output and efficiency with appropriate substantial economic returns in terms of progeny.
  • the admixture is fed at 250g/male pig/ day.
  • Figure 1 graph showing the spermatozoa concentration in semen from control and supplemented boars according to Group 2 in Table A;
  • Figure 2 graph showing mean spermatozoa concentration and total sperm number in the semen from control and supplemented boars according to Group 2 in Table A;
  • Figure 3 graph showing total born and born alive progeny to gilts inseminated with semen from control and supplemented boars according to Group 2 in Table A;
  • Figure 4 graph showing farrowing rate and fecundity for gilts inseminated with semen from control and supplemented boars according to Group 2 in Table A;
  • Figure 5 graph showing mean obtainable artificial inseminations per ejaculate for control and supplemented boars according to Group 2 in Table A.
  • the experimental groups consisted of matched (age, weight etc.) boars and gilts, from the same genetic stock and maintained under the conditions referred to above.
  • the diets were fed for 16 weeks with individual semen samples taken at day 0 and 4 week intervals thereafter for appropriate qualitative and quantitative investigations.
  • the major fatty acid components of the standard (basal) diet, the enriched DHA oil and GLA source (Evening Primrose Oil) are given below in Table 1.
  • Fatty acid compositions (wt. per cent of total fatty acids) of the basal diet and the supplemental high DHA and GLA oils.
  • the spermatozoa were harvested from the semen by gentle centrifugation as per standard commercial procedures well known in the art. The physiological and chemical measurements were then undertaken immediately and the parameters measured according to standard procedures well known in the art of semen production and spermatozoa physiology and biochemistry. Those parameters measured were as follows:
  • Total lipid content was extracted from the spermatozoa by an established procedure involving an exhaustive extraction with organic solvents. Lipid separation and quantification was then subsequently performed by thin layer chromatography. Fatty acid analysis of the lipids was performed again by established procedures involving transesterification and appropriate application to capillary gas liquid chromatography.
  • the fertilising capacity of the semen was measured in vivo by artificial insemination of gilts as per commercial practice and conception rates, fecundity (piglet numbers, born alive /dead etc.) recorded on an individual boar and gilt basis.
  • Table 2 shows the long chain polyunsaturated fatty acid compositional changes that occurred within the spermatozoa as a result of the supplemental addition outlined in this group. It can be seen that there was a substantial elevation in the level of DHA at the expense of a proportional reduction in that of DPA. In the supplemented group the level of DPA:DHA in the spermatozoa (in the supplemented boars at 16 weeks of feeding) was 13.8:45.5(wt per cent of total fatty acids) versus 25.1:32.8 in those fed the standard diet.
  • Fatty acid composition (wt. per cent of total fatty acids) of the phospholipid fraction of the spermatozoa from the control and DHA supplemented boars at 16 weeks of feeding.
  • antioxidants can also be used, such as plant extracts.
  • other fatty acids such as Stearadonic acid (n-3) also have been found to enhance fertility in accordance with this invention.
  • the pig is unique in displaying for one reason or another a high proportion of DPA at the expense of DHA within the lipid of the spermatozoa.
  • One of the advantages of the present invention is that now the promotion of male fertility in the pig under present intensive commercial production systems can be promoted through enhanced supplemental DHA availability to maximise the DHA level within the spermatozoa and its metabolic involvement in spermatozoa output, quality and functionality.
  • the present invention clearly demonstrates the ability to increase substantially the level of DHA at the expense of DPA in the spermatozoa of the modern commercial male breeding pig through supplemental dietary means.
  • supplemental polyunsaturates to be accompanied by additional dietary selenium which was accompanied by an enhanced glutathione peroxidase activity (group 2).
  • group 3 A further improvement on the spermatozoa features was effected by supplemental inclusion also of GLA (group 3).
  • the supplement herein described be used for livestock, in particular pigs, it is to be understood that due to the well known similarity between pigs and human biochemistry and physiology , the supplement would also find application in maximisation of human fertility and reproductive output.
  • the advantages of the present invention include the fact that the addition of a supplement based on a unique formulation of a high DHA containing oil and alpha-tocopherol influenced significantly the C22 polyunsaturate acid proportions within the spermatozoa and the proportion of DHA was considerably increased at the sole expense of DPA. Under these conditions there was a trend for a positive effect upon a range of spermatozoa features associated with fertilising capacity. With the addition of selenium to the supplement the effect of the fatty acid changes on the full range of spermatozoa fertilising features were all highly significant.
  • administering the semen from boars receiving the DHA/ a-T/ selenium supplement to gilts via artificial insemination effected a significant increase in fertilisation and progeny output as judged on a range of commercial parameters.
  • incorporation of GLA into the supplement further enhanced the semen quality of the boar.
  • the admixture provided by this application significantly extends, under semen storage conditions appropriate to artificial insemination, the maintenance within the spermatozoa of several features important to fertilising capacity.
  • the supplementation resulted in a highly significant increase in financial return.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un supplément comprenant un adjuvant contenant une source triacylglycérol enrichie d'acide docasahexanoïque (DHA), accompagnée d'au moins un antioxydant et de sélénium intervenant comme co-facteur majeur d'enzyme cationique destiné à protéger le DHA, et convenant pour favoriser la fertilité et l'issu de la reproduction chez l'homme et les autres animaux.
EP01940729A 2000-06-17 2001-06-18 Supplement visant augmenter la fertilite Withdrawn EP1292295A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0014758A GB2363331B (en) 2000-06-17 2000-06-17 Supplement to enhance fertility
GB0014758 2000-06-17
PCT/GB2001/002640 WO2001097802A1 (fr) 2000-06-17 2001-06-18 Supplément visant à augmenter la fertilité

Publications (1)

Publication Number Publication Date
EP1292295A1 true EP1292295A1 (fr) 2003-03-19

Family

ID=9893789

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01940729A Withdrawn EP1292295A1 (fr) 2000-06-17 2001-06-18 Supplement visant augmenter la fertilite

Country Status (4)

Country Link
EP (1) EP1292295A1 (fr)
AU (1) AU2001274232A1 (fr)
GB (1) GB2363331B (fr)
WO (1) WO2001097802A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003288606A1 (en) * 2002-12-20 2004-07-14 Pronova Biocare As Use of a fatty acid composition for treatment of male infertility
JP2013032288A (ja) * 2009-10-20 2013-02-14 Idemitsu Kosan Co Ltd 精子活力向上剤、受胎率向上剤、精子活力向上方法、及び受胎率向上方法
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
IL303815A (en) * 2020-12-22 2023-08-01 Purdue Research Foundation A method for selecting a young pig for breeding

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU204199B (en) * 1987-03-18 1991-12-30 Caola Kozmetikai Process for producing pharmaceutical compositions containing unsaturated fatty acids and selenium as active components
HU202088B (en) * 1987-03-18 1991-02-28 Caola Kozmetikai Method for producing dietetic preparation
HU210122B (en) * 1988-03-23 1995-02-28 Biorex Kutato Fejlesztoe Kft Process for production of composition against thromboembolytic conditions of circulating system and heart
WO1995026646A1 (fr) * 1994-04-01 1995-10-12 Abbott Laboratories Produit nutritif utilise dans le traitement de la rectocolite hemorragique et son utilisation
WO1998000125A1 (fr) * 1996-06-29 1998-01-08 The Scottish Agricultural College Amelioration de la fertilite male au moyen d'antioxydants et/ou d'acides gras polyinsatures
FR2761887B1 (fr) * 1997-04-11 1999-06-18 Roland Asmar Medicament visant a la prevention multifactorielle des maladies cardiovasculaires
ZA994296B (en) * 1998-04-01 2000-01-10 Agricultural Research Council A method of improving the reproductive performance of a sow.
IL125097A (en) * 1998-06-25 2003-01-12 Israel State Dietary manipulation to increase fertility
AU5791400A (en) * 1999-06-07 2000-12-28 Omegatech Inc. Methods for improving the functional status of sperm

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0197802A1 *

Also Published As

Publication number Publication date
GB2363331A8 (en) 2002-01-17
GB2363331A (en) 2001-12-19
WO2001097802A1 (fr) 2001-12-27
AU2001274232A1 (en) 2002-01-02
GB0014758D0 (en) 2000-08-09
GB2363331B (en) 2003-02-05

Similar Documents

Publication Publication Date Title
Fair et al. The effect of dietary n-3 polyunsaturated fatty acids supplementation of rams on semen quality and subsequent quality of liquid stored semen
Mitre et al. Oral intake of shark liver oil modifies lipid composition and improves motility and velocity of boar sperm
Estienne et al. Dietary supplementation with a source of omega-3 fatty acids increases sperm number and the duration of ejaculation in boars
Kelso et al. Lipid and antioxidant changes in spermatozoa and seminal plasma throughout the reproductive period of bulls
Brinsko et al. Effect of feeding a DHA-enriched nutriceutical on the quality of fresh, cooled and frozen stallion semen
Yeste et al. The effects on boar sperm quality of dietary supplementation with omega-3 polyunsaturated fatty acids differ among porcine breeds
Am-In et al. Lipid profiles of sperm and seminal plasma from boars having normal or low sperm motility
Surai et al. Effect of long-term supplementation with arachidonic or docosahexaenoic acids on sperm production in the broiler chicken
Masoudi et al. Effect of dietary fish oil supplementation on ram semen freeze ability and fertility using soybean lecithin–and egg yolk–based extenders
Murphy et al. The effect of dietary supplementation of algae rich in docosahexaenoic acid on boar fertility
MacDonald et al. Effects of linoleate and arachidonate deficiencies on reproduction and spermatogenesis in the cat
Zanussi et al. Dietary supplementation with flaxseed oil as source of omega-3 fatty acids improves seminal quality and reproductive performance in aged broiler breeder roosters
Adeel et al. Improvement of liquid and frozen-thawed semen quality of Nili-Ravi buffalo bulls (Bubalus bubalis) through supplementation of fat
Mattioli et al. Dietary fish oil and flaxseed for rabbit does: fatty acids distribution and Δ6-desaturase enzyme expression of different tissues
US6235783B1 (en) Male fertility with antioxidants and/or polyunsaturated fatty acids
Luo et al. The Effect of Maternal Diet with Fish Oil on Oxidative Stress and Inflammatory Response in Sow and New‐Born Piglets
Ezazi et al. The influence of dietary sunflower oil, rich in n‐6 polyunsaturated fatty acids, in combination with vitamin C on ram semen parameters, sperm lipids and fertility
Zarei et al. Egg yolk enriched with polyunsaturated fatty acids (PUFAs) improves the shelf life of ram semen in liquid storage
Abdi-Benemar et al. Effects of astaxanthin supplementation on the freezability, lipid peroxidation, antioxidant enzyme activities and post-thawing fertility of ram semen
Vizzarri et al. Lippia citriodora (verbascoside) extract supplementation: Effect on rabbit semen quality in vivo and in vitro
EP1292295A1 (fr) Supplement visant augmenter la fertilite
Lee et al. Effect of alpha-linolenic acid with bovine serum albumin or methyl-beta-cyclodextrin on membrane integrity and oxidative stress of frozen-thawed boar sperm
Maidin et al. In vitro supplements improves motility and progressive score of spermatozoa in jermasia goats
Yimer et al. The roles of antioxidants and fatty acids in sperm cryopreservation
Singh et al. Linseed oil in boar's diet improved in vivo fertility and antioxidant status

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 15/08 B

Ipc: 7A 61K 35/78 B

Ipc: 7A 61K 33/04 B

Ipc: 7A 61K 31/355 B

Ipc: 7A 61K 31/23 A

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060103